PortalPublikationenLong-term outcome of patients with newly diagnosed chronic m...

Long-term outcome of patients with newly diagnosed chronic myeloid leukemia-A randomized comparison of stem cell transplantation with drug treatment

Standard

Long-term outcome of patients with newly diagnosed chronic myeloid leukemia-A randomized comparison of stem cell transplantation with drug treatment. / Gratwohl, A; Pfirrmann, M; Zander, A; Kröger, N; Beelen, D; Novotny, J; Nerl, C; Scheid, C; Spiekermann, K; Mayer, J; Sayer, H G; Falge, C; Bunjes, D; Döhner, H; Ganser, A; Schmidt-Wolf, I; Schwerdtfeger, R; Baurmann, H; Kuse, R; Schmitz, N; Wehmeier, A; Fischer, J T; Ho, A D; Wilhelm, M; Goebeler, M-E; Lindemann, H W; Bormann, M; Hertenstein, B; Schlimok, G; Baerlocher, G M; Aul, C; Pfreundschuh, M; Fabian, M; Staib, P; Edinger, M; Schatz, M; Fauser, A; Arnold, R; Kindler, T; Wulf, G; Rosselet, A; Hellmann, A; Schäfer, E; Prümmer, O; Schenk, M; Hasford, J; Heimpel, H; Hossfeld, D K; Kolb, H-J; Büsche, G; Haferlach, C; Schnittger, S; Müller, M C; Reiter, A; Berger, U; Saußele, S; Hochhaus, A; Hehlmann, R.

in: LEUKEMIA, Jahrgang 30, Nr. 3, 03.2016, S. 562-9.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Gratwohl, A, Pfirrmann, M, Zander, A, Kröger, N, Beelen, D, Novotny, J, Nerl, C, Scheid, C, Spiekermann, K, Mayer, J, Sayer, HG, Falge, C, Bunjes, D, Döhner, H, Ganser, A, Schmidt-Wolf, I, Schwerdtfeger, R, Baurmann, H, Kuse, R, Schmitz, N, Wehmeier, A, Fischer, JT, Ho, AD, Wilhelm, M, Goebeler, M-E, Lindemann, HW, Bormann, M, Hertenstein, B, Schlimok, G, Baerlocher, GM, Aul, C, Pfreundschuh, M, Fabian, M, Staib, P, Edinger, M, Schatz, M, Fauser, A, Arnold, R, Kindler, T, Wulf, G, Rosselet, A, Hellmann, A, Schäfer, E, Prümmer, O, Schenk, M, Hasford, J, Heimpel, H, Hossfeld, DK, Kolb, H-J, Büsche, G, Haferlach, C, Schnittger, S, Müller, MC, Reiter, A, Berger, U, Saußele, S, Hochhaus, A & Hehlmann, R 2016, 'Long-term outcome of patients with newly diagnosed chronic myeloid leukemia-A randomized comparison of stem cell transplantation with drug treatment', LEUKEMIA, Jg. 30, Nr. 3, S. 562-9. https://doi.org/10.1038/leu.2015.281

APA

Gratwohl, A., Pfirrmann, M., Zander, A., Kröger, N., Beelen, D., Novotny, J., Nerl, C., Scheid, C., Spiekermann, K., Mayer, J., Sayer, H. G., Falge, C., Bunjes, D., Döhner, H., Ganser, A., Schmidt-Wolf, I., Schwerdtfeger, R., Baurmann, H., Kuse, R., ... Hehlmann, R. (2016). Long-term outcome of patients with newly diagnosed chronic myeloid leukemia-A randomized comparison of stem cell transplantation with drug treatment. LEUKEMIA, 30(3), 562-9. https://doi.org/10.1038/leu.2015.281

Vancouver

Gratwohl A, Pfirrmann M, Zander A, Kröger N, Beelen D, Novotny J et al. Long-term outcome of patients with newly diagnosed chronic myeloid leukemia-A randomized comparison of stem cell transplantation with drug treatment. LEUKEMIA. 2016 Mär;30(3):562-9. https://doi.org/10.1038/leu.2015.281

Bibtex

@article{cc0d6f5ad5ef479c9e619fdaba5b35b2,
title = "Long-term outcome of patients with newly diagnosed chronic myeloid leukemia-A randomized comparison of stem cell transplantation with drug treatment",
abstract = "Tyrosine kinase inhibitors represent today's treatment of choice in chronic myeloid leukemia (CML). Allogeneic hematopoietic stem cell transplantation (HSCT) is regarded as salvage therapy. This prospective randomized CML-study IIIA recruited 669 patients with newly diagnosed CML between July 1997 and January 2004 from 143 centers. Of these, 427 patients were considered eligible for HSCT and were randomized by availability of a matched family donor between primary HSCT (group A; N=166 patients) and best available drug treatment (group B; N=261). Primary endpoint was long-term survival. Survival probabilities were not different between groups A and B (10-year survival: 0.76 [95% CI: 0.69-0.82] vs 0.69 [95% CI: 0.61-0.76]), but influenced by disease and transplant risk. Patients with a low transplant risk showed superior survival compared to patients with high (P<0.001) and non-high risk disease (P=0.047) in group B; after entering blast crisis, survival was not different with or without HSCT. Significantly more patients in group A were in molecular remission (56 vs 39%; P=0.005) and free of drug treatment (56 vs 6%; P<0.001). Differences in symptoms and Karnofsky score were not significant. In the era of tyrosine kinase inhibitors, HSCT remains a valid option when both disease and transplant risk are considered.Leukemia accepted article preview online, 14 October 2015. doi:10.1038/leu.2015.281.",
author = "A Gratwohl and M Pfirrmann and A Zander and N Kr{\"o}ger and D Beelen and J Novotny and C Nerl and C Scheid and K Spiekermann and J Mayer and Sayer, {H G} and C Falge and D Bunjes and H D{\"o}hner and A Ganser and I Schmidt-Wolf and R Schwerdtfeger and H Baurmann and R Kuse and N Schmitz and A Wehmeier and Fischer, {J T} and Ho, {A D} and M Wilhelm and M-E Goebeler and Lindemann, {H W} and M Bormann and B Hertenstein and G Schlimok and Baerlocher, {G M} and C Aul and M Pfreundschuh and M Fabian and P Staib and M Edinger and M Schatz and A Fauser and R Arnold and T Kindler and G Wulf and A Rosselet and A Hellmann and E Sch{\"a}fer and O Pr{\"u}mmer and M Schenk and J Hasford and H Heimpel and Hossfeld, {D K} and H-J Kolb and G B{\"u}sche and C Haferlach and S Schnittger and M{\"u}ller, {M C} and A Reiter and U Berger and S Sau{\ss}ele and A Hochhaus and R Hehlmann",
year = "2016",
month = mar,
doi = "10.1038/leu.2015.281",
language = "English",
volume = "30",
pages = "562--9",
journal = "LEUKEMIA",
issn = "0887-6924",
publisher = "NATURE PUBLISHING GROUP",
number = "3",

}

RIS

TY - JOUR

T1 - Long-term outcome of patients with newly diagnosed chronic myeloid leukemia-A randomized comparison of stem cell transplantation with drug treatment

AU - Gratwohl, A

AU - Pfirrmann, M

AU - Zander, A

AU - Kröger, N

AU - Beelen, D

AU - Novotny, J

AU - Nerl, C

AU - Scheid, C

AU - Spiekermann, K

AU - Mayer, J

AU - Sayer, H G

AU - Falge, C

AU - Bunjes, D

AU - Döhner, H

AU - Ganser, A

AU - Schmidt-Wolf, I

AU - Schwerdtfeger, R

AU - Baurmann, H

AU - Kuse, R

AU - Schmitz, N

AU - Wehmeier, A

AU - Fischer, J T

AU - Ho, A D

AU - Wilhelm, M

AU - Goebeler, M-E

AU - Lindemann, H W

AU - Bormann, M

AU - Hertenstein, B

AU - Schlimok, G

AU - Baerlocher, G M

AU - Aul, C

AU - Pfreundschuh, M

AU - Fabian, M

AU - Staib, P

AU - Edinger, M

AU - Schatz, M

AU - Fauser, A

AU - Arnold, R

AU - Kindler, T

AU - Wulf, G

AU - Rosselet, A

AU - Hellmann, A

AU - Schäfer, E

AU - Prümmer, O

AU - Schenk, M

AU - Hasford, J

AU - Heimpel, H

AU - Hossfeld, D K

AU - Kolb, H-J

AU - Büsche, G

AU - Haferlach, C

AU - Schnittger, S

AU - Müller, M C

AU - Reiter, A

AU - Berger, U

AU - Saußele, S

AU - Hochhaus, A

AU - Hehlmann, R

PY - 2016/3

Y1 - 2016/3

N2 - Tyrosine kinase inhibitors represent today's treatment of choice in chronic myeloid leukemia (CML). Allogeneic hematopoietic stem cell transplantation (HSCT) is regarded as salvage therapy. This prospective randomized CML-study IIIA recruited 669 patients with newly diagnosed CML between July 1997 and January 2004 from 143 centers. Of these, 427 patients were considered eligible for HSCT and were randomized by availability of a matched family donor between primary HSCT (group A; N=166 patients) and best available drug treatment (group B; N=261). Primary endpoint was long-term survival. Survival probabilities were not different between groups A and B (10-year survival: 0.76 [95% CI: 0.69-0.82] vs 0.69 [95% CI: 0.61-0.76]), but influenced by disease and transplant risk. Patients with a low transplant risk showed superior survival compared to patients with high (P<0.001) and non-high risk disease (P=0.047) in group B; after entering blast crisis, survival was not different with or without HSCT. Significantly more patients in group A were in molecular remission (56 vs 39%; P=0.005) and free of drug treatment (56 vs 6%; P<0.001). Differences in symptoms and Karnofsky score were not significant. In the era of tyrosine kinase inhibitors, HSCT remains a valid option when both disease and transplant risk are considered.Leukemia accepted article preview online, 14 October 2015. doi:10.1038/leu.2015.281.

AB - Tyrosine kinase inhibitors represent today's treatment of choice in chronic myeloid leukemia (CML). Allogeneic hematopoietic stem cell transplantation (HSCT) is regarded as salvage therapy. This prospective randomized CML-study IIIA recruited 669 patients with newly diagnosed CML between July 1997 and January 2004 from 143 centers. Of these, 427 patients were considered eligible for HSCT and were randomized by availability of a matched family donor between primary HSCT (group A; N=166 patients) and best available drug treatment (group B; N=261). Primary endpoint was long-term survival. Survival probabilities were not different between groups A and B (10-year survival: 0.76 [95% CI: 0.69-0.82] vs 0.69 [95% CI: 0.61-0.76]), but influenced by disease and transplant risk. Patients with a low transplant risk showed superior survival compared to patients with high (P<0.001) and non-high risk disease (P=0.047) in group B; after entering blast crisis, survival was not different with or without HSCT. Significantly more patients in group A were in molecular remission (56 vs 39%; P=0.005) and free of drug treatment (56 vs 6%; P<0.001). Differences in symptoms and Karnofsky score were not significant. In the era of tyrosine kinase inhibitors, HSCT remains a valid option when both disease and transplant risk are considered.Leukemia accepted article preview online, 14 October 2015. doi:10.1038/leu.2015.281.

U2 - 10.1038/leu.2015.281

DO - 10.1038/leu.2015.281

M3 - SCORING: Journal article

C2 - 26464170

VL - 30

SP - 562

EP - 569

JO - LEUKEMIA

JF - LEUKEMIA

SN - 0887-6924

IS - 3

ER -